L’anticorps Souris Monoclonal anti-PD-L1 a été validé pour WB, FACS, ELISA, IF, ICC et IHC (p). Il convient pour détecter PD-L1 dans des échantillons de Humain.
N° du produit ABIN6992231
Aperçu rapide pour PD-L1 anticorps (Extracellular Domain) (ABIN6992231)
PD-L1
Reactivité: Humain
WB, IF, ICC
Hôte: Lapin
Polyclonal
unconjugated
Indications d'application
PD-L1 antibody can be used for detection of PD-L1 by Western blot at 0.25 - 0.5 μ,g/mL. Antibody can also be used for immunohistochemistry starting at 2 - 5 μ,g/mL. For immunofluorescence start at 5 μ,g/mL.
Antibody validated: Western Blot in human samples, Immunohistochemistry in human samples, Immunocytochemistry in human samples, Immunofluorescence in human samples and Flow Cytometry in mouse samples. All other applications and species not yet tested.
Restrictions
For Research Use only
Format
Liquid
Concentration
1 mg/mL
Buffer
PD-L1 Antibody is supplied in PBS containing 0.02 % sodium azide and 50 % glycerol.
Agent conservateur
Sodium azide
Précaution d'utilisation
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Stock
-20 °C,4 °C
Stockage commentaire
PD-L1 antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Antigène
PD-L1
(CD274 (PD-L1))
Autre désignation
PDL1
Sujet
PD-L1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC) (1). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC (2). PD-1 can bind two different but related ligands, PD-L1 and PD-L2. PD-L1 is a B7-related protein that inhibits cell-mediated immune responses by reducing the secretion of IL-2 and IL-10 from memory T cells (3). This suggests that PD-L1 may be useful in reducing allogenic CD4+ memory T-cell responses to endothelial cells, thereby reducing the likelihood of host immune responses to allografts. PD-L1 also functions as an immune checkpoint protein, and multiple anti-PD-L1 antibodies are currently in phase II and III clinical trials, with one antibody already approved for the treatment of cancer (4).